HMB 45 is an immuno-histological marker for
Wait, but there are other markers too, like S-100, HMB-45, and Melan-A. HMB 45 is particularly useful for malignant melanomas. It reacts with a 45 kDa melanosomal antigen found in melanocytes. So the correct answer here would be melanoma.
Now, looking at the options, even though they're not listed, the possible wrong answers could be other types of tumors. Let's say the options are for different cancers. For example, if an option says "Squamous cell carcinoma," that's incorrect because HMB 45 isn't used for that. Similarly, if there's an option for "Lymphoma" or "Adenocarcinoma," those are also incorrect. Another possible wrong answer might be "Neuroblastoma," but that's more associated with other markers like CD117 or synaptophysin.
I should also remember that HMB 45 is part of a panel used to diagnose melanomas, especially in uncertain cases. It's important to differentiate melanoma from other pigmented lesions. The clinical pearl here is that HMB 45 is a key marker for melanocytic tumors, and its presence supports a diagnosis of melanoma. So the correct answer is the option that states melanoma.
**Core Concept**
HMB 45 is a monoclonal antibody targeting a melanosomal antigen (gp100) expressed in melanocytes and melanocytic tumors. It is a key immunohistochemical marker used to diagnose melanomas and differentiate them from other pigmented lesions.
**Why the Correct Answer is Right**
HMB 45 reacts with a 45 kDa melanosomal protein in melanocytes and melanomas. It is highly specific for malignant melanomas, especially metastatic cases and spindle-cell variants. Unlike S-100, which is broader in reactivity (including schwannomas and Langerhans cells), HMB 45 is more specific for melanocytic differentiation. Its expression is retained in most melanomas, making it a cornerstone in melanoma diagnosis.
**Why Each Wrong Option is Incorrect**
**Option A:** If the option states "Squamous cell carcinoma," it is incorrect because HMB 45 is not expressed in keratinocytes or squamous tumors.
**Option B:** If the option states "Lymphoma," it is invalid since lymphomas lack melanocytic differentiation and do not express HMB 45.
**Option C/D:** If the option refers to "Neuroendocrine tumors" or "Adenocarcinoma," these are unrelated to melanocytic lineage and show no HMB 45 positivity.
**Clinical Pearl / High-Yield Fact**
HMB 45, along with Melan-A (A103) and S-100, forms a diagnostic panel for melanoma. A